Article
Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma.
Leukemia - 1 Aug 2020
Lenz Georg, Hawkes Eliza, Verhoef Gregor, Haioun Corinne, Thye Lim Soon, Seog Heo Dae, Ardeshna Kirit, Chong Geoffrey, Haaber Jacob, Shi Wei, Gorbatchevsky Igor, Lippert Susanne, Hiemeyer Florian, Piraino Paolo, Beckmann Georg, Peña Carol, Buvaylo Viktoriya, Childs Barrett H, Salles Gilles
Abstract excerpt
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have adverse outcomes. We evaluated the efficacy and safety of the phosphatidylinositol 3-kinase inhibitor copanlisib in patients with relapsed/refractory DLBCL and assessed the relationship between efficacy and DLBCL cell of origin (COO; activated B-cell like [ABC] and germinal center B-cell like [GCB]) and other biomarkers. The primary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.